iFAST Diagnostics Ltd has developed a breakthrough technology that delivers antimicrobial susceptibility testing (AST) results with speed, accuracy, and actionable clinical detail.
Antimicrobial resistance (AMR) has emerged as one of the defining health challenges of our time. As bacteria evolve and become increasingly resistant to existing treatments, the global community faces a mounting crisis that threatens to undermine decades of medical progress. Central to this challenge is the need for rapid, accurate identification of the most effective antibiotic for each patient.
iFAST Diagnostics Ltd, a spinout from the University of Southampton, is pioneering a breakthrough technology that has the potential to transform clinical practice, improve patient outcomes, and significantly slow the spread of AMR.
This article…